• Trevi Therapeutics recently reported that key results from its Phase 2b CORAL trial of oral nalbuphine ER for chronic cough in idiopathic pulmonary fibrosis were published in the Journal of the American Medical Association, with safety outcomes broadly consistent with prior studies.
• The data showed similar discontinuation rates between nalbuphine ER and placebo and fewer serious adverse events in the nalbuphine ER group, underscoring a potentially differentiated safety profile.
• Next, we’ll consider how publication of the CORAL trial results in a leading medical journal shapes Trevi Therapeutics’ investment narrative.

AI is about to change healthcare. These 111 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

What Is Trevi Therapeutics' Investment Narrative?

To own Trevi Therapeutics, you really have to believe that Haduvio can transition from a clinically interesting asset into a commercially viable product in tough, underserved cough indications, despite the company’s lack of revenue and ongoing losses. The recent JAMA publication of the CORAL Phase 2b data helps that story on the margin by reinforcing a clean, differentiated safety profile, which matters for physicians, regulators and potential partners, but it does not suddenly resolve the key near term catalysts or risks. The big drivers still sit around future efficacy data, regulatory dialogue and how Trevi funds itself without excessive dilution, especially with the stock already trading at a premium to many peers on book value. In that context, the JAMA paper looks more like a credibility boost than a thesis-changing event.

However, one risk in particular could catch new shareholders off guard if they miss it. Our expertly prepared valuation report on Trevi Therapeutics implies its share price may be too high.

Exploring Other Perspectives

The Simply Wall St Community’s two fair value views on Trevi span US$21.80 to US$35.00, underlining how far apart expectations can be. Against that backdrop, the stock’s premium price to book and Trevi’s ongoing losses give you a sense of how dependent future performance is on successful execution of the Haduvio program and disciplined capital management.

Explore 2 other fair value estimates on Trevi Therapeutics - why the stock might be worth just $21.80!

Build Your Own Trevi Therapeutics Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Trevi Therapeutics research is our analysis highlighting 3 important warning signs that could impact your investment decision.
• Our free Trevi Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Trevi Therapeutics' overall financial health at a glance.

Contemplating Other Strategies?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.
• Explore 22 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.